Vanda Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:VNDA) | MetaTrader

Open full chart

Financials

Overview Relatórios Statistics Dividends

Quarterly Annual

Total assets 645.12 M656.2 M631.94 M624.75 M601.14 M488.95 M Total liabilities 103.89 M117.66 M120.52 M138.42 M135.14 M161.76 M Total equity 541.22 M538.55 M511.42 M486.33 M466 M327.19 M Total liabilities & shareholders' equities 645.12 M656.2 M631.94 M624.75 M601.14 M488.95 M Total debt —————— Net debt ——————

Notícias

FDA aceita pedido da Vanda para imsidolimab no tratamento de doença rara de pele

Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug - Vanda Pharmaceuticals (NASDAQ:VNDA)

American Express, Oracle among market cap stock movers on Monday

H.C. Wainwright eleva preço-alvo da Vanda Pharmaceuticals para US$ 24 após aprovação da FDA

Vanda Pharmaceuticals stock price target raised to $24 by H.C. Wainwright on FDA approval

Why Is Vanda Pharmaceuticals Stock Soaring On Monday? - Vanda Pharmaceuticals (NASDAQ:VNDA)

Stock Market Today: Dow Jones, S&P 500 Futures Drop After Supreme Court Strikes Down Trump's Emergency Tariffs— Novo Nordisk, Strategy, Vanda In Focus - State Street SPDR S&P 500 ETF Trust (ARCA:SPY)

Ações da Vanda Pharmaceuticals disparam após FDA aprovar novo medicamento para Bipolar I

Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug

FDA aprova Bysanti da Vanda para transtorno bipolar e esquizofrenia

FDA approves Vanda’s Bysanti for bipolar disorder, schizophrenia

Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript